Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, received new equity awards. On February 10, 2026 he was granted 6,100 non-qualified stock options with an exercise price of $284.5 per share, vesting in three equal annual installments beginning February 10, 2027.
He was also granted 2,020 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments starting February 10, 2027. After this grant, he holds 6,100 options and 4,910 RSUs directly.
Labcorp Holdings Inc. director Garheng Kong reported an equity award of restricted stock units. On February 10, 2026, Kong acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock. These units vest fully on February 10, 2027.
Following this grant, Kong beneficially owns 1,670 Restricted Stock Units, held directly. This filing reflects a stock-based compensation award rather than an open-market purchase or sale.
Labcorp Holdings Inc. director Paul Rothman reported an equity award in the form of Restricted Stock Units. On February 10, 2026, he acquired 733 Restricted Stock Units as a grant, each representing the right to receive one share of Labcorp common stock if vesting conditions are met.
These Restricted Stock Units vest fully on February 10, 2027. Following this grant, Rothman beneficially holds a total of 1,670 Restricted Stock Units in a direct ownership capacity, aligning his compensation more closely with the company’s future share performance.
Labcorp Holdings Inc. director John H. Sampson received an equity award of 773 restricted stock units on February 10, 2026. The Form 4 reports this as an acquisition of derivative securities at a price of $0 per unit, held as direct beneficial ownership.
Each restricted stock unit represents the contingent right to receive one share of Labcorp common stock. The 773 restricted stock units vest fully on February 10, 2027, and the filing shows 773 derivative securities beneficially owned following the reported transaction.
Labcorp Holdings Inc. director Kathryn E. Wengel received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported at a price of $0 per unit as a grant, not an open-market purchase.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp common stock, and the units vest fully on February 10, 2027. Following this grant, Wengel beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Richelle P. Parham received a new equity award in the form of restricted stock units. On February 10, 2026, she acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock, at no cash cost.
The Restricted Stock Units vest fully on February 10, 2027, meaning the shares will be delivered if the vesting conditions are satisfied. After this grant, Parham beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Peter M. Neupert reported an equity award under a company plan. On February 10, 2026, he received 773 Restricted Stock Units (RSUs)
The RSUs vest fully on February 10, 2027, meaning he will receive the underlying shares if vesting conditions are met. After this grant, Neupert beneficially owns 1,670 RSUs in total, all held as direct ownership.
Labcorp Holdings Inc. director Kirsten M. Kliphouse acquired 773 Restricted Stock Units on February 10, 2026 as an equity grant. Each unit represents the right to receive one share of Labcorp common stock. These units vest in full on February 10, 2027, subject to the award terms.
Following this grant, Kliphouse beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership. The transaction was reported as a grant, award, or other acquisition at a price of $0 per unit.
Labcorp Holdings Inc. director Jeffrey A. Davis received an equity grant of 773 Restricted Stock Units on February 10, 2026. Each unit represents the right to receive one share of Labcorp common stock. The Restricted Stock Units vest fully on February 10, 2027.
After this award, Davis beneficially owns a total of 1,670 Restricted Stock Units in Labcorp through direct ownership, reflecting his aggregate RSU holdings as reported.
Labcorp Holdings Inc. director Victor Bulto Carulla was granted 773 Restricted Stock Units (RSUs) on February 10, 2026, as reported in a Form 4 insider filing. Each RSU represents the contingent right to receive one share of Labcorp common stock.
The RSUs vest fully on February 10, 2027, meaning the director must remain eligible through that date to receive the underlying shares. Following this grant, the director beneficially owns 909 RSUs in total, all held in a direct ownership capacity.